• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Emergent BioSolutions Could See Further Upside Gains

Most of the indicators are still bullish in this name, although some profit-taking may be occurring.
By BRUCE KAMICH
Aug 13, 2020 | 09:11 AM EDT
Stocks quotes in this article: EBS, NVAX, JNJ

For his second "Executive Decision" segment of Mad Money Wednesday night, Jim Cramer also spoke with Robert Kramer, president and CEO of Emergent BioSolutions Inc. (EBS) , the vaccine and therapeutics maker working hard to fight COVID-19. Shares of Emergent are up 37.5% over just the past month.

Kramer said Emergent is proud to do everything it can to help with the COVID-19 pandemic. He remained "cautiously optimistic" with the vaccine progress that's been made so far, but noted that with six major players all with candidates in development, "it will be only a matter of time" before we have a successful treatment available.

When asked about their role in vaccine development, Kramer pointed out that Emergent has partnered with companies like Novavax (NVAX) to provide development support for their vaccine, among others. Emergent is also the U.S. supply chain partner for Johnson & Johnson's (JNJ) vaccine candidate and will provide the manufacturing muscle to help bring millions of doses to market.

We last looked at EBS on May 26 and wrote, "If you are long EBS from December, continue to hold risking a close below $79 now. If you have no position and like the fundamentals of EBS I would look to go long around $85 risking a close below $79. The $150 area is our longer-term price objective." Let's check in again on the charts and indicators.

In this updated daily bar chart of EBS, below, we can see that prices broke lower in June and would have stopped out our suggested recommendation. Prices rebased around $70 and eventually resumed the uptrend. Now, EBS is trading around $130 and not all that far from our original price target of $150. Prices are above the rising 50-day moving average line and the rising 200-day moving average line, telling us that the intermediate-term and longer-term trends are up.

The On-Balance-Volume (OBV) line did not dip much in June when prices declined below our stop suggestion and the line moved up into July, telling us that buyers of EBS have been more aggressive. Weakness in the OBV line since the middle of July suggests at least a degree of profit-taking.

The trend-following Moving Average Convergence Divergence (MACD) oscillator is above the zero line and bullish, but we can see that the two moving averages that comprise this indicator are narrowing. A take-profits sell signal could develop in the days ahead.

In this weekly bar chart of EBS, below, we can see a positive-looking chart. Prices are in an uptrend as they trade above the rising 40-week moving average line. The weekly OBV line has been strong since the middle of 2019, but shows a possible "hiccup" in the past few weeks. The MACD oscillator is very bullish and shows no signs of weakness.

In this Point and Figure chart of EBS, below, we used daily price data, and here the chart suggests a $225 price target.

Bottom line strategy: If you happen to still be long EBS, I would suggest a stop below $110. The $150 area is our first price target and then $225 is possible longer term.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Health Care Equipment & Services | Mad Money | Executive Interview | U.S. Equity | Coronavirus

More from Investing

You Bet Your BP I'd Be a Buyer

Mark Sebastian
Aug 16, 2022 2:32 PM EDT

With oil down over the last two days, BP's stock has held up.

Doug Kass: We May Now Be Approaching Another Important Top in the Market

Doug Kass
Aug 16, 2022 1:30 PM EDT

To justify buying at today's prices means that one expects a new Bull Market leg - something I remain dubious of.

Cisco, Long a Steady Tech Stock, Is Under the Microscope Ahead of Earnings

Brad Ginesin
Aug 16, 2022 12:45 PM EDT

Some top analysts are flashing a yellow light on the network equipment maker ahead of its quarterly report and amid tightening competition. But is caution really warranted for long-term investors?

2 Big-Name, Single-Stock ETFs With a Foreign Twist Could Be on the Horizon

Mark Abssy
Aug 16, 2022 12:00 PM EDT

The potential offerings from Roundhill aren't geared solely to the retail investor but also could interest smaller institutions and other ETF issuers.

This Market Needs Some Corrective Action

James "Rev Shark" DePorre
Aug 16, 2022 11:18 AM EDT

It's likely to occur on a rolling basis and won't be that evident in the senior indexes.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login